February 07, 2025

BioMed X Institute and Merck Successfully Complete Extrachromosomal DNA in Cancer Research Project

BioMed X Institute and Merck Successfully Complete Extrachromosomal DNA in Cancer Research Project

The research of BioMed X team EDC – Extrachromosomal DNA in Cancer – has uncovered critical insights into the mechanisms driving extrachromosomal DNA (ecDNA) formation and maintenance, offering potential avenues for novel cancer therapies.

Heidelberg, Germany, February 6, 2025. BioMed X, a German independent research institute, announces the successful completion of its oncology research project in partnership with Merck. The data generated by this project has been acquired by Merck for further development, potentially leading to new therapeutic approaches in precision oncology.

Launched in August 2022, the collaboration aimed to unravel the mechanisms behind the formation, propagation, and impact of ecDNA in cancer cells using state-of-the-art single-cell screening and spatial technologies. The project was led by Dr. Alexandros Drainas, winner of the BioMed X Innovation Boot Camp, and mentored by Dr. Sebastian M. Waszak, Assistant Professor at EPFL, Lausanne, Switzerland. Industry guidance provided by Dr. Balca Mardin, Head of Target Discovery & Research at Merck.

The multidisciplinary BioMed X team made significant strides in understanding ecDNA biology by addressing fundamental questions, such as:

  • How can we detect and trace ecDNA?
  • How is ecDNA formed, and which genes promote or inhibit its formation?
  • How are ecDNA structures formed, propagated, and maintained?

The team’s research identified genes that may reduce ecDNA abundance in cancer cells. Additionally, Team EDC developed advanced spatial technologies to explore how ecDNA localization affects cancer cell adaptability. The project was completed earlier than expected thanks to the promising and unexpected results achieved by the team. These early findings may offer promising strategies for mitigating cancer heterogeneity and reducing the mechanisms driving therapeutic resistance, potentially improving the efficacy of existing treatments.

Dr. Thomas Rückle, Senior Vice President Research at the BioMed X Institute, emphasized the importance of this achievement: “Our collaboration with Merck has once again demonstrated the power of combining academic curiosity with industrial expertise. The knowledge gained from this project not only advances cancer research but also showcases the potential of ecDNA-targeted therapies. We look forward to continuing our successful partnership with Merck and our joint journey towards a deeper understanding of complex life-threatening diseases.”

Our latest News

discover more
Therapeutic vaccination against HPV-related tumors: Nanoparticles make the difference

Therapeutic vaccination against HPV-related tumors: Nanoparticles make the difference

Researchers from the German Cancer Research Center (DKFZ) have collaborated with the SILVACX project group at Heidelberg University to develop a therapeutic vaccination concept that can mobilize the immune system to target cancer cells. The team showed that virus peptides coupled to silica nanoparticles can elicit effective T-cell responses against HPV-related tumors. In a mouse […]

ERC Awards Four Starting Grants to Universität Heidelberg

ERC Awards Four Starting Grants to Universität Heidelberg

European Research Council funds groundbreaking projects by early-career researchers The European Research Council is awarding four valuable grants to Heidelberg University. These ERC Starting Grants go to researchers in early stages of their career who want to carry out groundbreaking research with ERC funding. They include Dr Michael Gerlt, who will do research at the […]

New Headquarters – PL BioScience Announces Major Site Expansion in September 2025

New Headquarters – PL BioScience Announces Major Site Expansion in September 2025

Key Milestone for PL BioScience as new headquarters are announced PL BioScience announced the next major step in its expansion – an upcoming move to a new 1,200 m² facility in Aachen, in September 2025. This key milestone will support the company’s growth and upscaling efforts, and provide the world’s largest HPL output, with 20,000L […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp